AstraZeneca PLC - American Depositary Shares (AZN)

Olema Pharmaceuticals (NASDAQ:OLMA) has become the latest focal point of biotech volatility and executive opportunism. Following a staggering 300% surge in its share price over the past year—fueled by a "rising tide" effect in the breast cancer treatment market—top insiders have begun offloading significant portions of their

LAS VEGAS — In a landmark keynote that has redefined the trajectory of high-performance computing, Advanced Micro Devices, Inc. (NASDAQ:AMD) Chair and CEO Dr. Lisa Su took the stage at CES 2026 to announce the company’s transition into the "yotta-scale" era of artificial intelligence. Centered on the full reveal of the Instinct MI400 series and [...]

As the global markets open for the first week of 2026, a clear narrative has emerged: the "recovery plays" of 2025 have officially transformed into the "expansion leaders" of the new year. Following a blockbuster 2025 that saw the S&P 500 buoyed by a stabilizing interest rate environment and

Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s (IRA) negotiation provisions. This milestone represents a fundamental shift in the federal government’s role in drug

As of today, December 22, 2025, Pfizer Inc. (NYSE: PFE) stands as a case study in corporate reinvention and the brutal reality of the post-pandemic "hangover." Once the darling of the global healthcare sector during the peak of the COVID-19 crisis, the pharmaceutical giant is currently navigating one of the most challenging chapters in its [...]

This rising star in quantum computing is a high-risk but potentially high-reward play.

MIchaelAaron Flicker is the co-author of "Hacking The Human Mind: The Behavioral Science Secrets Behind 17 of the World's Best Brands."

AstraZeneca (AZN) shows a top technical rating and a high-quality consolidation pattern, signaling a potential breakout opportunity for technical traders.

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

The stocks listed here trade at forward earnings multiples of less than 18.

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

The New Year is shaping up to be an important one for this quantum computing stock.

The report states that the agreement between the U.S. and the U.K. is expected to be announced in the coming days.

Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries.

Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA.

AstraZeneca (AZN) is a top-quality stock for long-term investors, showing strong revenue growth, high profitability, and solid cash flow generation.

The company is wasting little time figuring out the particulars of a sweeping capital investment program.

AstraZeneca receives FDA approval for Koselugo to treat adults with NF1 and inoperable plexiform neurofibromas, backed by strong Phase 3 data.

A lot can happen for this quantum computing leader over the next decade.

Johnson & Johnson said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics.

November 14, 2025 – Quantum computing pioneer IonQ (NYSE: IONQ) recently captured significant market attention, with its stock experiencing a notable 3.6% gain on November 5, 2025, driven by an impressive upward revision of its revenue forecasts. This positive momentum was further underscored by a key insider purchase just days

The company inches closer to bringing a new drug to a very large addressable market.

The artificial intelligence (AI) sector is currently navigating a period of unprecedented dynamism, characterized by explosive technological advancements, massive capital inflows, and a palpable tension between investor optimism and concerns over valuation. As of November 2025, the AI market stands at a pivotal juncture, with a concentrated surge in mega-cap AI players driving overall market [...]

AstraZeneca's Baxdrostat cut blood pressure by 14 mmHg in the Phase 3 Bax24 trial, showing strong efficacy and safety in resistant hypertension patients.